SCHEMBL7349151

SCHEMBL7349151

Nc1nnc(-c2ccc(Cl)cc2)c(N)n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1A1 P48729 1/20 0.66
CLK4 Q9HAZ1 1/20 0.66
NPC1 O15118 2/20 0.60
RAB9A P51151 2/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
NPSR1 Q6W5P4 1/20 0.60
RXFP1 Q9HBX9 1/20 0.60
ADORA2A P29274 9/20 0.58
ADORA1 P30542 9/20 0.58
CYP2D6 P10635 2/20 0.50
ADRA1A P35348 2/20 0.50
MAOA P21397 1/20 0.50
MAPK1 P28482 1/20 0.50
SCN4A P35499 1/20 0.50
BLM P54132 1/20 0.50
PMP22 Q01453 1/20 0.50
PDE3A Q14432 1/20 0.50
SCN5A Q14524 1/20 0.50
SCN9A Q15858 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17838938 0.85 CSNK1A1 (0.57) CSNK1A1CLK4NPC1RAB9AMEN1
SCHEMBL979231 0.80 CSNK1A1 (0.92) CSNK1A1CLK4ADORA2AADORA1CYP2D6
SCHEMBL2326954 0.80 CSNK1A1 (0.66) CSNK1A1CLK4NPSR1ADORA2AADORA1
SCHEMBL3929311 0.80 ADORA2A (0.62) CSNK1A1CLK4NPC1RAB9AMEN1
SCHEMBL6492186 0.79 CSNK1A1 (0.55) CSNK1A1CLK4NPC1RAB9AADORA2A
SCHEMBL2323073 0.79 ADORA2A (0.79) CSNK1A1CLK4ADORA2AADORA1ADORA2B
SCHEMBL30186651 0.79 ADORA2A (0.79) CSNK1A1CLK4ADORA2AADORA1ADORA2B
SCHEMBL976667 0.79 CSNK1A1 (1.00) CSNK1A1CLK4ADORA2AADORA1CYP2D6
SCHEMBL12922467 0.78 CSNK1A1 (0.63) CSNK1A1CLK4NPC1RAB9AMEN1
SCHEMBL975779 0.78 CSNK1A1 (0.53) CSNK1A1CLK4NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6329521-B2 Process for preparing substituted benzoyl cyanide amidinohydrazones CHEMAGIS, LTD. (IL) 2001-12-11 US disclosed
US-20010025118-A1 Process for preparing substituted benzoyl cyanide amidinohydrazones CHEMAGIS LTD. (IL) 2001-09-27 US disclosed
EP-1127873-A2 Process for preparing substituted Benzoyl Cyanide Amidinohydrazones Chemagis Ltd. (IL) 2001-08-29 EP disclosed
US-4602017-A Substituted aromatic compounds SMITHKLINE BEECHAM CORPORATION(A PENNSYLVANIA CORPORATION) 1986-07-22 US disclosed
EP-0064158-A1 Omega-cyano-1, omega-diphenyl azalcane derivatives, their preparation and pharmaceutical preparations containing them BASF Aktiengesellschaft (DE) 1982-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010025118-A1 Process for preparing substituted benzoyl cyanide amidinohydrazones SLC6A19, CPS1, SLC1A5 CSNK1A1 1672/4885CLK4 3931/4885NPC1 1716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.